Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep;5(9):e1221.
doi: 10.1371/journal.pntd.0001221. Epub 2011 Sep 27.

Innovative partnerships for drug discovery against neglected diseases

Palle H Jakobsen  1 , Ming-Wei Wang, Solomon Nwaka
Affiliations

Innovative partnerships for drug discovery against neglected diseases

Palle H Jakobsen et al. PLoS Negl Trop Dis. 2011 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Examples of public–private partnerships in drug discovery against neglected diseases.
NCDS - The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Contribution: provides infrastructure and expertise to conduct high-throughput screening (HTS) and identification of leads for pharmaceutical development, as well as training of fellows from developing countries. NN - Novo Nordisk A/S. Contribution: supply of compound libraries, expertise with pharmaceutical research, development, and commercialization activities. WHO - World Health Organization Special Programme for Research and Training in Tropical Diseases (WHO/TDR). Contribution: oversees the management and technical review of the collaboration, supplies molecular targets through academic collaborators to support HTS, provides access to screening, medicinal chemistry, and DMPK networks, and sponsors fellows from Africa to be trained at NCDS as part of the collaboration.
Figure 2
Figure 2. NCDS scientists and African fellows are analyzing the results obtained from a TDR commissioned HTS campaign against a molecular target in tuberculosis (July 2009).
See this image and copyright information in PMC

References

    1. Nwaka S, Ridley R. Virtual drug discovery and development for neglected diseases through public private partnership. Nat Rev Drug Disc. 2003;2:919–828. - PubMed
    1. Moran M. A breakthrough in R&D for neglected diseases: new ways to get the drugs we need. PLoS Med. 2005;2:e302. doi: 10.1371/journal.pmed.0020302. - DOI - PMC - PubMed
    1. Moran M, Guzman J, Ropars A-L, McDonald A, Jameson N, et al. Neglected disease research and development: how much are we really spending? PLoS Med. 2009;6:e1000030. doi: 10.1371/journal.pmed.1000030. - DOI - PMC - PubMed
    1. Nwaka S, Ramirez B, Brun R, Maes L, Douglas F, et al. Advancing drug innovation for neglected diseases - criteria for lead progression. PLoS Negl Trop Dis. 2009;3:e440. doi: 10.1371/journal.pntd.0000440. - DOI - PMC - PubMed
    1. Nwaka S, Hudson A. Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov. 2006;5:941–955. - PubMed

Publication types

MeSH terms

Substances